Enhanced killing of chordoma cells by antibody-dependent cellmediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

Oncotarget

Volumn 7, Issue 23, 2016, Pages 33498-33511

  Fujii, Rika ^a   Friedman, Eitan R ^a   Richards, Jacob ^a   Tsang, Kwong Y ^a   Heery, Christopher R ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity (ADCC); Cancer stem cells; Chordoma; Immunotherapy; Programmed death ligand 1 (PD L1)

Indexed keywords

AVELUMAB; BRACHYURY PROTEIN; CCAAT ENHANCER BINDING PROTEIN; GAMMA INTERFERON; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CELL LINE; CANCER STEM CELL; CD8+ T LYMPHOCYTE; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CELL SUBPOPULATION; CHEMOSENSITIVITY; CHORDOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; JHC7 CELL LINE; MONOTHERAPY; MUG CHOR1 CELL LINE; NATURAL KILLER CELL; NORMAL HUMAN; PD L1 GENE; PROTEIN EXPRESSION; PROTEIN INDUCTION; U CH2 CELL LINE; UM CHOR1 CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CELL LINE, TUMOR; CHORDOMA; HUMANS; LYMPHOCYTE ACTIVATION;

EID: 84973637725     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9256     Document Type: Article

References (55)

1. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM and Baker LH. Chordoma: the nonsarcoma primary bone tumor. The oncologist. 2007; 12:1344-1350.
2. Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT and Ferreira MJ. Chordoma: current concepts, management, and future directions. The Lancet Oncology. 2012; 13:e69-76.
3. Stacchiotti S and Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. The Lancet Oncology. 2015; 16:e71-83.
4. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, Boshoff C and Flanagan AM. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006; 209:157-165.
5. Shen J, Li CD, Yang HL, Lu J, Zou TM, Wang DL and Deng M. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. Journal of clinical neuroscience. 2011; 18:96-99.
6. Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM and Kelley MJ. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nature genetics. 2009; 41:1176-1178.
7. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Bruderlein S, Moller P, Leithner A, Liegl B, Amary FM, Athanasou NN, et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. The Journal of pathology. 2011; 223:327-335.
8. Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, Berisha F, Flicek P, Stemple DL, Stern CD, Wardle FC and Flanagan AM. An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. The Journal of pathology. 2012; 228:274-285.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366:2443-2454.
10. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515:563-567.
11. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM and Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of clinical oncology. 2015; 33:1430-1437.
12. Topalian SL, Drake CG and Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer cell. 2015; 27:450-461.
13. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY and Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer immunology research. 2015; 3:1148-1157.
14. Feng Y, Shen J, Gao Y, Liao Y, Cote G, Choy E, Chebib I, Mankin H, Hornicek F and Duan Z. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. Oncotarget. 2015; 6:11139-11149. doi:10.18632/oncotarget.3576.
15. Mathios D, Ruzevick J, Jackson CM, Xu H, Shah S, Taube JM, Burger PC, McCarthy EF, Quinones-Hinojosa A, Pardoll DM and Lim M. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. Journal of neurooncology. 2015; 121:251-259.
16. Torres MJ, Ruiz-Cabello F, Skoudy A, Berrozpe G, Jimenez P, Serrano A, Real FX and Garrido F. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue antigens. 1996; 47:372-381.
17. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F and Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. Journal of the National Cancer Institute. 2013; 105:1172-1187.
18. Hsu W, Mohyeldin A, Shah SR, Ap Rhys CM, Johnson LF, Sedora-Roman NI, Kosztowski TA, Awad OA, McCarthy EF, Loeb DM, Wolinsky JP, Gokaslan ZL and Quinones Hinojosa A. Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. Journal of neurosurgery. 2011; 115:760-769.
19. Owen JH, Wang AC and Garrison AW. Establishment and characterization of two novel human chordoma cell lines. Meeting abstract from the 2014 Annual meeting of the a century of progress in head & neck cancer. 2014.
20. Bruderlein S, Sommer JB, Meltzer PS, Li S, Osada T, Ng D, Moller P, Alcorta DA and Kelley MJ. Molecular characterization of putative chordoma cell lines. Sarcoma. 2010; 2010:630129.
21. Rinner B, Froehlich EV, Buerger K, Knausz H, Lohberger B, Scheipl S, Fischer C, Leithner A, Guelly C, Trajanoski S, Szuhai K and Liegl B. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. International journal of oncology. 2012; 40:443-451.
22. Mauvezin C, Sancho A, Ivanova S, Palacin M and Zorzano A. DOR undergoes nucleo-cytoplasmic shuttling, which involves passage through the nucleolus. FEBS letters. 2012; 586:3179-3186.
23. Tsai VW, Mohammad MG, Tolhurst O, Breit SN, Sawchenko PE and Brown DA. CCAAT/enhancer binding protein-delta expression by dendritic cells regulates CNS autoimmune inflammatory disease. The Journal of neuroscience. 2011; 31:17612-17621.
24. Valente T, Straccia M, Gresa-Arribas N, Dentesano G, Tusell JM, Serratosa J, Mancera P, Sola C and Saura J. CCAAT/enhancer binding protein delta regulates glial proinflammatory gene expression. Neurobiology of aging. 2013; 34:2110-2124.
25. Furuse M, Fujita K, Hiiragi T, Fujimoto K and Tsukita S. Claudin-1 and-2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. The Journal of cell biology. 1998; 141:1539-1550.
26. Suzuki T, Yoshinaga N and Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. The Journal of biological chemistry. 2011; 286:31263-31271.
27. Solimini NL, Liang AC, Xu C, Pavlova NN, Xu Q, Davoli T, Li MZ, Wong KK and Elledge SJ. STOP gene Phactr4 is a tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:E407-414.
28. Anegon I, Cuturi MC, Trinchieri G and Perussia B. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. The Journal of experimental medicine. 1988; 167:452-472.
29. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J and Palena C. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine. Oncotarget. 2013; 4:1777-1790. doi:10.18632/oncotarget.1295.
30. Miettinen M, Wang Z, Lasota J, Heery C, Schlom J and Palena C. Nuclear Brachyury Expression Is Consistent in Chordoma, Common in Germ Cell Tumors and Small Cell Carcinomas, and Rare in Other Carcinomas and Sarcomas: An Immunohistochemical Study of 5229 Cases. The American journal of surgical pathology. 2015; 39:1305-1312.
31. Aydemir E, Bayrak OF, Sahin F, Atalay B, Kose GT, Ozen M, Sevli S, Dalan AB, Yalvac ME, Dogruluk T and Ture U. Characterization of cancer stem-like cells in chordoma. Journal of neurosurgery. 2012; 116:810-820.
32. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology. 2010; 28:3167-3175.
33. Chen DS, Irving BA and Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clinical cancer research. 2012; 18:6580-6587.
34. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M and Nakajima Y. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clinical cancer research. 2007; 13:2151-2157.
35. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, et al. PD-L1 expression in triplenegative breast cancer. Cancer immunology research. 2014; 2:361-370.
36. Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D and Bertucci F. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6:5449-5464. doi:10.18632/oncotarget.3216.
37. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E and Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8:793-800.
38. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT and Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science translational medicine. 2013; 5:200ra116.
39. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I and Mandai M. IFN-gamma from lymphocytes induces PD L1 expression and promotes progression of ovarian cancer. British journal of cancer. 2015; 112:1501-1509.
40. Yan C and Higgins PJ. Drugging the undruggable: transcription therapy for cancer. Biochimica et biophysica acta. 2013; 1835:76-85.
41. Hamilton DH, Litzinger MT, Fernando RI, Huang B and Palena C. Cancer vaccines targeting the epithelialmesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Seminars in oncology. 2012; 39:358-366.
42. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya LL, Baranova AV, Kozlov AP and Schlom J. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clinical cancer research. 2007; 13:2471-2478.
43. Heery CR, Singh BH, Rauckhorst M, Marte JL, Donahue RN, Grenga I, Rodell TC, Dahut W, Arlen PM, Madan RA, Schlom J and Gulley JL. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury. Cancer immunology research. 2015; 3:1248-1256.
44. Gameiro SR, Malamas AS, Bernstein MB, Tsang KY, Vassantachart A, Sahoo N, Tailor R, Pidikiti R, Guha CP, Hahn S, M., Krishnan S and Hodge JW. Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. International Journal of Radiation Oncology, Biology, Physics. 2016:In-Press.
45. Ljunggren HG and Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nature reviews Immunology. 2007; 7:329-339.
46. Moore F, Santin I, Nogueira TC, Gurzov EN, Marselli L, Marchetti P and Eizirik DL. The transcription factor C/EBP delta has anti-apoptotic and anti-inflammatory roles in pancreatic beta cells. PloS one. 2012; 7:e31062.
47. Balamurugan K and Sterneck E. The many faces of C/EBPdelta and their relevance for inflammation and cancer. International journal of biological sciences. 2013; 9:917-933.
48. Dawood S, Austin L and Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014; 28:1101-1107, 1110.
49. Ebben JD, Treisman DM, Zorniak M, Kutty RG, Clark PA and Kuo JS. The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert opinion on therapeutic targets. 2010; 14:621-632.
50. Keysar SB and Jimeno A. More than markers: biological significance of cancer stem cell-defining molecules. Molecular cancer therapeutics. 2010; 9:2450-2457.
51. Pan Q, Li Q, Liu S, Ning N, Zhang X, Xu Y, Chang AE and Wicha MS. Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells. 2015; 33:2085-2092.
52. Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, Yang J, Xu SL, Ye XZ, Xu C, Yang L, Qian C, Wang JM, Cui YH, Zhang X and Bian XW. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer research. 2014; 74:5746-5757.
53. Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R, Mandelboim O, Stassi G, Di Fabrizio E, Parmiani G, Moretta A, Dieli F, et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol. 2013; 190:2381-2390.
54. Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, Rodell TC, Schlom J and Tsang KY. Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer immunology, immunotherapy. 2014; 63:1307-1317.
55. Hamilton DH, Fernando RI, Schlom J and Palena C. Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody. Oncotarget. 2015; 6:4853-4862. doi:10.18632/oncotarget.3086.